Best Life Sciences Companies in Morrisville, United States
The 35 best Life Sciences companies in Morrisville, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Small Bone Innovations.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Morrisville
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Small Bone Innovations Suite of orthopedic products for small bones and joints | $181M | 177 mo ago | 68 | — | Acquired | 41 patents Small joint orthopedic implants for ankle fusion and wrist hemiarthroplasty | — |
| 2 | Metabolon Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine | $173M | 19 mo ago | 189 189 → 203 (+7%) | — | Series H | 400 patents Metabolomics biomarker discovery and diagnostic assays for metabolic and inflammatory diseases | — |
| 3 | TearScience Innovating eye health solutions for a lifetime of clear vision | $151M | 125 mo ago | 35 | — | Acquired | 202 patents Non‑invasive ocular surface imaging and meibomian gland diagnostics for dry‑eye assessment | — |
| 4 | OptiNose Developer of smart devices for nasal drug delivery | $120M | 28 mo ago | 132 | — | Acquired | 45 patents Intranasal drug delivery devices and methods for administering pharmaceuticals through the nose | — |
| 5 | Novan Developer of Nitric Oxide based therapeutics for dermatology disorders | $102M | 74 mo ago | 89 89 → 106 (+19%) | — | Public | 227 patents Topical pharmaceutical formulations for nitric‑oxide, antiviral, and wound‑healing applications | — |
| 6 | Arrivo BioVentures Developing biologics and small molecules for conditions that are affected by processes in the Central Nervous… | $94M | 34 mo ago | 11 | Stephen Butts Co-Founder & CEO | Series B | — | — |
| 7 | Liquidia Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions | $90M | 65 mo ago | 63 | Damian Degoa Director | Public | 120 patents Patents concentrated in transport & manufacturing processes | 7 job openings |
| 8 | nContact Epicardial ablation devices | $68M | 142 mo ago | 14 | Sidney Fleischman Co-Founder | Acqui-Hired | — | — |
| 9 | nContact Surgical Cardiac ablation technology | $51M | 162 mo ago | 14 | John Funkhouser CEO & President | Acquired | 81 patents Surgical devices for vacuum-assisted tissue coagulation and atrial remodeling prevention | — |
| 10 | Envisia Therapeutics Envisia Therapeutics is a biotechnology company focused on the research and development of novel ocular… | $40M | 126 mo ago | 26 | Bill Yelle Chairman & CEO | Series A | — | — |
| 11 | Sapheon Closure system for treatment of venous reflux disease | $36M | 154 mo ago | 20 | — | Acquired | 21 patents Venous insufficiency treatment devices and sterilization of medical adhesives | — |
| 12 | Codetta Online platform for analyzing omics clinical data | $27M | 28 mo ago | 21 | — | Series A | — | — |
| 13 | Oriel Therapeutics Develops respiratory care drugs | $26M | 226 mo ago | — | Paul Atkins President & CEO | Acqui-Hired | 148 patents Patents concentrated in health & consumer products | — |
| 14 | Portray Developer of intraoral 3D Tomosynthesis dental X-ray system | $25M | 39 mo ago | 19 | David Vance CEO | Series B | — | — |
| 15 | Saga Diagnostics Provider of tests for detection and analysis of circulating tumor DNA | $18M | 62 mo ago | 23 | Lao Saal Founder | Acquired | — | — |
| 16 | Aerial BioPharma Developing pain management therapeutics | $11M | 155 mo ago | 1 | Stephen Butts Co-Founder & CEO | Deadpooled | 21 patents Carbamate-based pharmaceutical compounds for treating cataplexy (sleep disorder) | — |
| 17 | Lq3 Pharmaceuticals Developer of oral health therapies using microparticle and nanoparticle drug delivery systems | $10M | 141 mo ago | 6 | Kyle Chenet ex-CEO | Deadpooled | — | — |
| 18 | Gusto Global Developer of microbiome technology to detect infectious diseases | $6M | 48 mo ago | 4 | — | Series A | 30 patents Targeted amplicon sequencing for disease diagnostics and microbial‑based therapeutic composition design. | — |
| 19 | Jellatech Provider of animal-free collagen and gelatin products for multiple industries | $6M | 37 mo ago | 7 | Stephanie Michelsen Co-Founder & CEO | Seed | 10 patents Cultured-cell derived collagen/gelatin production for biomaterials and tissue engineering | — |
| 20 | Protochips Electron microscopy products and analytical tools for studying nanoscale materials | $4M | 43 mo ago | 40 40 → 44 (+10%) | — | Series A | 182 patents In situ TEM instrumentation for drift correction, temperature control, and electrochemical analysis | — |
| 21 | Inhalon Biopharma Developing inhaled antibody treatments for acute respiratory infections, a clinical-stage biotechnology… | $2M | 13 mo ago | 8 | — | Seed | — | — |
| 22 | Neuronex Nasal spray formulation of diazepam to treat epilepsy. | $2M | 184 mo ago | — | — | Acqui-Hired | 5 patents Intranasal benzodiazepine drug delivery formulations for rapid CNS therapy | — |
| 23 | SOV Therapeutics Oral testosterone replacement therapies for adult men | $425K | 178 mo ago | — | — | Seed | — | — |
Top 12 Life Sciences companies in Morrisville
#1
Series H · Morrisville, North Carolina · founded 2000 · 189 employees$173.4Mraised▾
Provider of solutions for biomarker discovery, diagnostic tests, and personalized medicine. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. It also offers Quantose IR, a lab test for prediabetes assessment and treatment, and Meta IMD, a CLIA assay for inborn errors of metabolism. The company is also developing metabolomics-based clinical diagnostic tests that may improve the early detection of obesity-related metabolic diseases.
- Feb 2025Grant (prize money)$297.7K
- Dec 2024Series H$7.5M
- May 2024Grant (prize money)$298.3K
- Sep 2023Grant (prize money)$297.7K
#2
Seed · Morrisville, North Carolina · founded 2018 · 8 employees$2Mraised▾
Developing inhaled antibody treatments for acute respiratory infections, a clinical-stage biotechnology company focused on creating revolutionary treatments. They are rapidly advancing programs for multiple respiratory infections, addressing the unmet need for effective treatments against active infections directly in the lung. Their innovative inhaled drug platform aims to provide superior effectiveness and at-home convenience, simplifying respiratory care through a "test-to-treat" model. They are developing a pipeline of proprietary inhaled antibody treatments for respiratory syncytial virus, influenza, human metapneumovirus, and SARS-CoV-2. This biotechnology company is dedicated to improving patient outcomes through advanced therapeutic solutions.
- Aug 2025Grant (prize money)$2M
- May 2025Grant (prize money)$2M
- Apr 2025Grant (prize money)$2M
- Feb 2025Grant (prize money)$2M
#3
Acquired · Morrisville, Pennsylvania · founded 2000 · 132 employees$120.5Mraised▾
OptiNose is a developer of smart devices for nasal drug delivery. The drug delivery devices can be used for powder and liquid formulations. Pipeline includes candidates for chronic nasal inflammatory disease, migraine and autism.
- May 2024Post IPO$4.7M
- Nov 2021Post IPO$4M
- Aug 2020Post IPO$250K
- Sep 2019Post IPO$5.4M
#4
Series B · Morrisville, North Carolina · founded 2015 · 11 employees$94.2Mraised▾
Arrivo BioVentures is focused primarily on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. Arrivo’s team will source and acquire development candidates in or ready for the early stages of human clinical trials and move the projects through clinical proof-of-concept and the next significant valuation inflection point.
#5
Series A · Morrisville, North Carolina · founded 2021 · 21 employees$27.3Mraised▾
Online platform for analyzing omics clinical data. The platform offers analysis of reagents, hardware, and software enabling simultaneous, multiplexed, and multi-omic analyses of liquid biopsy and isolated DNA, RNA, and protein.
- May 2024Series A$12.3M
- Apr 2022Series A$15M
#6
Series B · Morrisville, North Carolina · founded 2015 · 19 employees$25.3Mraised▾
Developer of intraoral 3D Tomosynthesis dental X-ray system. It offers a Portray system and software that uses 3D Tomosynthesis to reconstruct X-rays taken from several angles into a 3D volume of images of the patient’s teeth. It provide information regarding caries, fractures, endodontic issues, periodontic conditions, and other oral pathologies.
- Jun 2023Series B$4.4M
- Apr 2019Series B$25.3M
#7
Public · Morrisville, North Carolina · founded 2004 · 63 employees$90.3Mraised▾
Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions. The company uses proprietary PRINT particle engineering technology to develop YUTREPIA inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
- Apr 2021Post IPO$21.7M
- Jan 2020Post IPO$22.4M
- Feb 2018Series D$25.5M
- May 2013Grant (prize money)$1.9M
#8
Public · Morrisville, North Carolina · founded 2006 · 89 employees$101.8Mraised▾
Developer of Nitric Oxide based therapeutics for dermatology disorders. The technology is based on their proprietary platform called Nitricil, which enables the creation of new nitric oxide-based NCEs for topical formulations. The lead candidate is used for the treatment of acne vulgaris. Other candidates include the treatment of HPV, onychomycosis, psoriasis, and atopic dermatitis.
- Jul 2020Post IPO$5M
- Feb 2020Grant (prize money)$1M
- Sep 2019Grant (prize money)$1.1M
- Sep 2019Grant (prize money)$1.1M
#9
Acquired · Morrisville, Pennsylvania · founded 2004 · 68 employees$181.4Mraised▾
Small Bones Innovations (SBi) makes devices for small bones and joints, particularly focusing on trauma and arthroplasty. The company markets its products in more than 35 countries worldwide. The company was acquired by orthopedic devices firm Stryker in Jun 2014 in an all-cash transaction for up to $375M.
- Dec 2011Conventional Debt$43M
- Dec 2010Series F$15M
- Dec 2010Series E$4.2M
- May 2010Series E$12M
#10
Acquired · Morrisville, Pennsylvania · founded 2005 · 35 employees$150.7Mraised▾
Innovating eye health solutions for a lifetime of clear vision. Dedicated to solving vision needs and innovating for a healthier, sustainable future. The organization provides care for patients at every stage of their eye health journey, from contact lenses to cataract surgery. With a history of innovation, they offer an all-encompassing portfolio of solutions to transform patients’ lives. They collaborate to advocate, educate, and expand global access to care. Their mission is to help patients see their world clearly, addressing conditions like myopia, presbyopia, astigmatism, dry eye (including Meibomian Gland Dysfunction), and cataracts. They offer treatments including contact lenses and laser vision correction. They provide resources for eye care professionals and support the AdvaMed Code of Ethics.
- Apr 2016Series D$19.2M
- Feb 2013Series D$70M
- May 2010Series C$44.5M
- 2007Series B$15M
#11
Seed · Morrisville, North Carolina · founded 2020 · 7 employees$5.5Mraised▾
Provider of animal-free collagen and gelatin products for multiple industries. Its technologies produce gelatin and collagen from cells instead of from animals. The company offers cell-based collagen and gelatin ingredient which can be used in foods, candies, cosmetics, pharmaceuticals, and more.
- Aug 2023Seed$3.5M
- Feb 2022Seed—
- Apr 2021Seed$2M
#12
Acqui-Hired · Morrisville, North Carolina · founded 2005 · 14 employees$67.7Mraised▾
nContant has developed the EPi-Sense and Numeris Coagulation System and VisiTrax epicardial ablation device for treatment of atrial fibrillation. The EPi-Sense and Numeris Coagulation System with VisiTrax have CE Mark Approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. It integrates suction, perfusion, and radiofrequency energy to ensure cardiac tissue contact and energy transmission to create linear lesions on a beating heart. Numeris with VisiTrax is also indicated for endoscopic coagulation of cardiac tissue in the United States.
- Nov 2014Series D$20M
- Mar 2013Series D$6.7M
- Jan 2012Conventional Debt$433.8K
- Nov 2010Series C$16.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.